Clindamycin phosphate, a parenteral preparation of the antibiotic clindamycin, was used to treat 131 patients with documented bacterial infections. Clindamycin therapy effectively eradicated 81% of the infections. There were no apparent systemic toxic effects. Injections of clindamycin phosphate were satisfactorily tolerated for as long as three weeks. Resistant Staphylococcus aureus developed in 8% of the cases.
Thus, parenterally administered clindamycin phosphate appears to be safe and effective in treating serious surgical infections due to gram-positive organisms and shows promise in treating anaerobic infections.